Cyprus/Greece/MaltaCyprusGreeceMalta

Greece

08.05.2004

Athens - The Helenic Society for the Study and Applications of Growth Hormones will hold the 2nd International Congress on Adult Consequences of Childhood Endocrine Diseases from May 6-8 in Athens. Main topics are going to be the adipose tissue as an endocrine organ as well as growth and growth hormone therapy. The proceedings will be published as a supplement on Pediatric Endo-crinology Reviews (PER).
Further information: Prof. G. E. Krassas (krassas@the.forthnet.gr, www.ghsociety.gr)

Cyprus/Greece/MaltaCyprusGreeceMalta

19.03.2008

Athens – Greek conglomerate Alapis is further expanding its healthcare arm (production of veterinary pharmaceuticals, medical equipment and nutritional supplements), an area that made up 75% of its total EBITDA of €117.3m in...

Cyprus/Greece/MaltaCyprusGreeceMalta

24.09.2007

Athens – Greek chemical and human and veterinary pharmaceutical company Alapis S.A., which was formed in May by a merger of the Greek firms Veterin, Ebik and Elpharma, is expanding rapidly through acquisitions in south-eastern...

Cyprus/Greece/MaltaCyprusGreeceMalta

11.07.2007

Athens – At the end of May, Greece has launched its official site for the Greek National Contact Point (NCP) for the FP7’s thematic areas “Health“ and “Food, Agriculture and Fisheries, and Biotechnology“ (www.ncp-bionova.gr/)....

Cyprus/Greece/MaltaCyprusGreeceMalta

16.05.2007

Athens – Greek Deputy Agriculture Minister Alexandros Kontos has renewed a decree banning the sale of genetically engineered Mon810 Bt maize varieties for another 18 months after an ultimatum of the European Commission ran out in...

Cyprus/Greece/MaltaCyprusGreeceMalta

16.03.2007

Ioannina – Tumor markers are specific to a certain type of cancer and its developmental stage. They are used to estimate a prognosis for the development and treatment of the cancer. Researchers led by John Ioannidis from the...

Politics / Law, Cyprus/Greece/MaltaCyprusGreeceMalta

21.11.2006

Athens – The Greek government and the European Investment Fund (EIF) signed a Memorandum of Understanding in October, which is to implement ‘Jeremie’. The initiative allows the EU Member States and regions to use part of their...

Cyprus/Greece/MaltaCyprusGreeceMalta

12.05.2006

Athens/Napa - Senetek PLC, a US-biopharmaceutical company focused on developing and co-marketing products in the key categories skincare and dermatological worldwide, announced in March that they have signed a cooperative...

Cyprus/Greece/MaltaCyprusGreeceMalta

17.03.2006

Athens/Paris - US-based drug development company Immuno-Designed Molecules (IDM) Inc. signed in February an exclusive licensing and marketing agreement for its cancer drug Junovan (Muramyl Tripeptide Phosphatidylethanolamine) in...

Cyprus/Greece/MaltaCyprusGreeceMalta

17.03.2006

Athens/Brussels - The European Commission has decided that the Greek national ban of MON810 maize is not properly justified and has therefore ordered to lift the ban. Up to now, Greece had referred to the safeguard clause for...

Cyprus/Greece/MaltaCyprusGreeceMalta

29.01.2006

Athens/Nikosia - Drug developer Samaritan Europe has entered into an exclusive distribution agreement with Three Rivers Pharmaceuticals for the marketing and sales of Amphocil® (amphotericin B cholesteryl sulfate complex for...

Displaying results 11 to 20 out of 47

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-cyprus-greece-malta/browse/1/article/greece-2.html

Stock list

All quotes

TOP

  • MAGFORCE (D)5.90 EUR9.26%
  • ABCAM (UK)387.00 GBP7.72%
  • NANOBIOTIX (F)17.40 EUR7.27%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.40 EUR-8.33%

TOP

  • WILEX (D)3.12 EUR300.0%
  • SANTHERA (CH)69.30 CHF103.8%
  • ADDEX (CH)4.07 CHF82.5%

FLOP

  • MERCK KGAA (D)63.71 EUR-50.0%
  • HYBRIGENICS (F)1.72 EUR-34.4%
  • PROSENSA (NL)9.24 USD-24.4%

TOP

  • SANTHERA (CH)69.30 CHF3453.8%
  • GW PHARMACEUTICALS (UK)438.00 GBP800.9%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.25 CHF-92.6%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)8.87 EUR-71.8%

No liability assumed, Date: 23.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events